Monoclonal Antibodies Against CLAUDIN-18 for Treatment of Cancer
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application PCT/EP2006/011302, filed Nov 24, 2006. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,017,564 | Monoclonal Antibodies Against CLAUDIN-18 for Treatment of Cancer In force · High confidence | Tron - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz Gemeinnützige GmbH | In force | High confidence | ||
| US 10,738,108 | Monoclonal Antibodies Against CLAUDIN-18 for Treatment of Cancer In force · High confidence | Tron - Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz Gemeinnutzige GmbH | In force | High confidence | ||
| US 11,739,139 | Monoclonal Antibodies Against CLAUDIN-18 for Treatment of Cancer In force · High confidence | Astellas Pharma Inc. | In force | High confidence | ||
| US 9,751,934 | Monoclonal Antibodies Against CLAUDIN-18 for Treatment of Cancer In force · High confidence | Astellas Pharma Inc. | In force | High confidence | ||
| US 10,174,104 | Monoclonal Antibodies Against CLAUDIN-18 for Treatment of Cancer In force · High confidence | Tron - Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz Gemeinnutzige GmbH | In force | High confidence | ||
| US 8,168,427 | Monoclonal Antibodies Against CLAUDIN-18 for Treatment of Cancer In force · High confidence | Astellas Pharma Inc. | In force | High confidence | ||
| US 9,212,228 | Monoclonal Antibodies Against Claudin-18 For Treatment of Cancer In force · High confidence | Astellas Pharma Inc. | In force | High confidence | ||
| US 9,499,609 | Monoclonal Antibodies Against CLAUDIN-18 for Treatment of Cancer In force · High confidence | Astellas Pharma Inc. | In force | High confidence | ||
| Application 18/352,430 | Monoclonal Antibodies Against CLAUDIN-18 for Treatment of Cancer Pending Not granted | Astellas Pharma Inc. | Pending | Not granted |
9 of 9 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Astellas Pharma Inc..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.